Outcome of cytomegalovirus retinitis in immunocompromised patients without Human Immunodeficiency Virus treated with intravitreal ganciclovir injection
To study the outcomes of treatment with intravitreal ganciclovir injection for cytomegalovirus (CMV) retinitis in patients without Human Immunodeficiency Virus (HIV) infection.
In this retrospective cohort study, demographic and clinical characteristics of patients with CMV retinitis without HIV were noted. Patients received intravitreal ganciclovir injection (2 mg/0.1 ml) alone until quiescence. The outcome measures were time taken for the lesions to heal, number of injections, change in best-corrected visual acuity (BCVA), recurrence of retinitis, occurrence of immune recovery uveitis (IRU) or injection-related complications and retinal detachment (RD).
18 eyes of ten patients (six males) with mean age of 33.7 years from June 2004 to March 2013 were included. Thirteen eyes with active lesions (mean BCVA of 0.51 ± 0.41) received 5.54 ± 3.36 intravitreal ganciclovir injections with complete healing within 1.81 ± 1.25 months. The final BCVA was 0.43 ± 0.52. IRU was observed in six eyes (33.33 %) and RD developed in one eye. One eye had recurrence 1 month after stopping ganciclovir injections. The rest of the patients had recurrence-free follow-up at 9.46 ± 12.42 months.
Non-HIV patients with CMV retinitis can be successfully treated with intravitreal ganciclovir injection alone, avoiding the systemic side effects of systemic anti-CMV therapy.
KeywordsCytomegalovirus retinitis Ganciclovir Intravitreal injection Non HIV CMV retinitis Intravitreal ganciclovir Viral retinitis
Declaration of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
Authors have no financial disclosure/proprietary interest. No conflicting relationship exists for any author.
- 5.Pathanapitoon K, Tesavibul N, Choopong P, Boonsopon S, Kongyai N, Ausayakhun S, Kunavisarut P, Rothova A (2013) Clinical manifestations of cytomegalovirus-associated posterior uveitis and panuveitis in patients without Human Immunodeficiency Virus infection. JAMA Ophthalmol 131:638–645PubMedCrossRefGoogle Scholar
- 15.Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group (1992) Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 326:213–220CrossRefGoogle Scholar
- 16.Studies of Ocular Complications of AIDS Research Group (1995) Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of the Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Arch Intern Med 155:65–74CrossRefGoogle Scholar
- 17.Griffy KG (1996) Pharmacokinetics of oral ganciclovir capsules in HIV-infected persons. AIDS 10:3–6Google Scholar
- 28.Komanduri KV, Viswathanan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, McCune JM (1998) Restoration of cytomegalovirus specific CD4+ T lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 4:953–956PubMedCrossRefGoogle Scholar